Key result
Thiazolidinediones inhibited human cardiac myofibroblast proliferation in a concentration-dependent manner (0.1-10 micromol/L) via a PPARgamma-independent mechanism.
Why the study?
Do thiazolidinediones reduce human cardiac myofibroblast proliferation?
Do thiazolidinediones reduce human cardiac myofibroblast proliferation?
Thiazolidinediones inhibit human cardiac myofibroblast proliferation via a PPARgamma-independent mechanism, potentially contributing to their ability to modulate adverse myocardial remodelling.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for cardiac remodeling; does not support clinical use without further study.
Mughal et al. (2008) studied Myocardial remodelling. Thiazolidinediones (ciglitazone, rosiglitazone, troglitazone) and 15d-PGJ2 vs. PPARgamma antagonists (GW9662 or T0070907) was evaluated on Cardiac myofibroblast proliferation, migration, invasion, and matrix metalloproteinase secretion. Thiazolidinediones inhibited human cardiac myofibroblast proliferation in a concentration-dependent manner (0.1-10 micromol/L) via a PPARgamma-independent mechanism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: